Novartis lays off more in New York; DEA approves Xcelience to make Class 1 schedule drugs

> Florida-based CDMO Xcelience has been granted DEA approval to make Class I schedule drugs. Report

> Novartis ($NVS) will lay off 89 more workers starting June 30 at its Diovan plant in Suffern, NY. Report

> CDMO Recipharm has competed a serialization project in Korea for Abbott. Release

> Fusion Pharmaceuticals is recalling more than 9,400 Dicopanol kits for mixing diphenhydramine hydrochloride because of microbial contamination. Recall

> The Mississippi attorney general has asked a judge to keep the identity of the state's execution-drug supplier secret while he appeals an order to release the name. Story


Suggested Articles

CureVac and Tesla are teaming up to produce the German vaccine maker's molecular RNA printers, Tesla CEO Elon Musk tweeted Thursday.

The FDA knocked a California compounding pharmacy facility for a suite of sanitary concerns, including the presence of ants in the plant.

Merck Animal Health will plow $100 million into its DeSoto, Kansas, plant to scale up production of animal vaccines.